Publications
Seven Cholrem papers. A decade of independent science behind them.
Cholrem’s human work is published and open access. The independent literature it builds on is listed below it, so that nothing here needs to be taken on trust.
Cholrem research
Human studies, 2019–2026
Led by Kyle Hodgetts, Cholrem Pty Ltd, with co-authors from Griffith University and clinical practice. Open access.
2026 · In peer reviewThree-vessel coronary disease cleared on rectal HPβCD: a case reportSevere three-vessel disease, bypass declined, arteries patent on CT at 11 and 23 months. Submitted to a cardiology journal.
2026Regression of Established Coronary Artery Calcification via a Specialized High-Viscosity Rectal Formulation of 2-Hydroxypropyl-β-Cyclodextrin (Cavadex): A Multi-Center Longitudinal Analysis Challenging the Paradigm of Irreversible AtherosclerosisHodgetts KCardiology Research and Cardiovascular Medicine · PDF
2026Regression of Atherosclerotic Plaque via High-Viscosity 2-Hydroxypropyl-β-Cyclodextrin (Cavadex): A Multi-Center Retrospective Case SeriesHodgetts K, Roberts JCardiology Research and Cardiovascular Medicine · PDF
2025Symptomatic Improvement and Enhanced Quality of Life in Individuals with Atherosclerotic Cardiovascular Disease Following a 12-Week Self-Monitored Regimen of Rectally Administered 2-Hydroxypropyl-β-Cyclodextrin (Cavadex): An Observational StudyHodgetts K125 participants · Cardiology Research and Cardiovascular Medicine · PDF
2025Cyclodextrin Therapy for Atherosclerotic Cardiovascular Disease: A Case Series on Plaque Regression and Symptomatic ImprovementHodgetts K, Roberts JC, Howes LGCardiology Research and Cardiovascular Medicine · PDF
Study 2021 · Published 20242-Hydroxypropyl-β-Cyclodextrin Induces Rapid Regression of Atherosclerotic Plaque and Reduces Hyperlipidaemia in Adult with Cardiovascular DiseaseHodgetts K, Howes L, Fang YY, Song ZMCarotid plaque on ultrasound and blood lipids after intravenous HPβCD · Cardiology Research and Cardiovascular Medicine
Study 2019 · Published 20242-Hydroxypropyl-β-Cyclodextrin Reduces Atherosclerotic Plaques in Human Coronary ArteryHodgetts K, Demian M, Fang YY, Song ZMThe founder’s coronary angiograms before and after intravenous HPβCD. The first human arterial imaging on HPβCD · Cardiology Research and Cardiovascular Medicine
2026 · SynthesisCavadex and the Predicted Result: Human Plaque Regression on HPβCD Across Seven PapersPrediction ledger: nine of twelve findings predicted by independent science before Cholrem observed them. In preparation.
Independent literature
The science Cholrem builds on
None of these papers was written or funded by Cholrem.
2016 · AtherosclerosisCyclodextrin promotes atherosclerosis regression via macrophage reprogrammingZimmer S, et al. Science Translational Medicine 2016;8:333ra50. University of Bonn.
2012 · Alzheimer’sNeuroprotection by cyclodextrin in cell and animal models of Alzheimer’s diseaseYao J, et al. Journal of Experimental Medicine 2012;209:2501–2513. Weill Cornell Medical College.
2016 · ReviewCyclodextrins as emerging therapeutic tools in the treatment of cholesterol-associated vascular and neurodegenerative diseasesCoisne C, et al. Molecules 2016;21:1748.
2017 · Human safetyIntrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1Ory DS, et al. The Lancet 2017;390:1758–1768. Phase 1–2a trial, US National Institutes of Health.
2026 · NeurologyHydroxypropyl-β-cyclodextrin and novel cyclodextrins resolve myelin-debris foam cellsWuerch EC, et al. Neurotherapeutics 2026;23:e00943.
1992 · DeliveryRectal absorption of hydroxypropyl-β-cyclodextrinArima H, et al. Journal of Pharmaceutical Sciences 1992;81:1119. Approximately one quarter of the dose absorbed from the rectum in an animal model.
2026 · RegulatoryUS FDA approval of Lembaz™ (adrabetadex, HPβCD) for Niemann-Pick disease type CBeren Therapeutics, November 2026. The first cyclodextrin approved as a medicine.
2026 · FieldFDA clears IND for an engineered cyclodextrin in coronary artery diseaseCyclarity Therapeutics UDP-003, November 2026, following a Phase 1 study at Monash University’s Victorian Heart Institute. CT coronary angiography is the study’s imaging measure.